back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-03-08 17:46 Tx date 2024-03-04 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-9,000 vol |
201,000 | |
| Filed 2023-09-15 17:52 Tx date 2023-09-12 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+108,000 vol |
210,000 | |
| Filed 2022-11-19 12:10 Tx date 2022-11-15 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+36,000 vol |
102,000 | |
| Filed 2021-11-19 20:45 Tx date 2021-11-15 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+30,000 vol |
227,700 | |
| Filed 2021-06-06 16:26 Tx date 2021-06-02 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$77,636
+17,551 vol $4.42 each |
26,662 | |
| Filed 2021-03-06 12:50 Tx date 2021-03-03 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$3,002
+583 vol $5.15 each |
9,111 | |
| Filed 2021-03-03 20:20 Tx date 2021-03-01 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$8,977
+1,697 vol $5.29 each |
8,528 | |
| Filed 2021-02-27 17:03 Tx date 2021-02-23 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$10,086
+1,581 vol $6.38 each |
6,831 | |
| Filed 2021-01-15 18:52 Tx date 2021-01-11 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+102,700 vol |
197,700 | |
| Filed 2020-12-17 18:35 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
37 - Stock split or consolidation
|
-855,000 vol |
95,000 | |
| Filed 2020-12-17 18:34 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-594,000 vol |
66,000 | |
| Filed 2020-12-17 18:33 Tx date 2020-12-01 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-47,250 vol |
5,250 | |
| Filed 2020-09-25 14:50 Tx date 2020-09-24 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$17,850
+52,500 vol $0.34 each |
52,500 | |
| Filed 2020-06-06 14:24 Tx date 2020-06-02 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-32,450
-55,000 vol $0.59 each |
0 | |
| Filed 2020-06-06 14:23 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-90,000
-150,000 vol $0.60 each |
55,000 | |
| Filed 2020-06-06 14:21 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$49,500
+150,000 vol $0.33 each |
205,000 | |
| Filed 2020-06-06 14:21 Tx date 2020-06-01 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-49,500
-150,000 vol $0.33 each |
660,000 | |
| Filed 2019-11-28 13:32 Tx date 2019-11-28 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+400,000 vol |
950,000 | |
| Filed 2018-10-11 Tx date 2018-10-10 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$18,700
+55,000 vol $0.34 each |
55,000 | |
| Filed 2018-10-05 Tx date 2018-10-03 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
97 - Other
|
+550,000 vol |
550,000 | |
| Filed 2018-10-05 Tx date 2013-06-10 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-04-28 Tx date 2018-04-26 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$47,850
+330,000 vol $0.145 each |
0 | |
| Filed 2018-04-28 Tx date 2018-04-26 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-47,850
-330,000 vol $0.145 each |
810,000 | |
| Filed 2018-04-28 Tx date 2018-04-24 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
40 - Short sale
|
$-9,600
-24,000 vol $0.40 each |
-330,000 | |
| Filed 2018-04-28 Tx date 2018-04-24 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
40 - Short sale
|
$-26,932.50
-66,500 vol $0.405 each |
-306,000 | |
| Filed 2018-04-28 Tx date 2018-04-24 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
40 - Short sale
|
$-70,930
-173,000 vol $0.41 each |
-239,500 | |
| Filed 2018-04-28 Tx date 2013-06-10 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-04-28 Tx date 2018-04-24 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
40 - Short sale
|
$-27,930
-66,500 vol $0.42 each |
-66,500 | |
| Filed 2017-04-03 Tx date 2017-03-31 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$60,000
+300,000 vol $0.20 each |
1,140,000 | |
| Filed 2016-03-11 Tx date 2016-03-09 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$65,249
+450,000 vol $0.145 each |
840,000 | |
| Filed 2015-07-24 Tx date 2015-07-13 |
$ATE
Antibe Therapeutics Inc. |
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$21,000
+150,000 vol $0.14 each |
390,000 |